专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明授权

EP2155892B1 NOUVEAUX SUBSTRATS DE PEPTIDASE 有权
标题翻译：中性粒细胞基质
公开(公告)号：EP2155892B1
公开(公告)日：2015-03-18
申请号：EP08805880.5
申请日：2008-05-29
申请人： BIOMERIEUX
发明人： FABREGA, Olivier , JAMES, Arthur , SALWATURA, Vindhya Lakshika , ORENGA, Sylvain , STANFORTH, Stephen
IPC分类号： C12Q1/04 , C12Q1/37 , C07D235/18 , C07D241/44 , C07D263/56 , C07D277/66 , C07K5/06
CPC分类号： C12Q1/04 , C07D235/18 , C07D241/44 , C07D263/57 , C07D277/66 , C12Q1/045 , C12Q1/37

93. 发明授权

EP1935986B1 Luminogenic and fluorogenic compounds and methods to detect molecules or conditions 有权
标题翻译：和用于检测分子或痛苦的发光的，荧光化合物和方法
公开(公告)号：EP1935986B1
公开(公告)日：2014-04-16
申请号：EP08151520.7
申请日：2006-05-31
申请人： PROMEGA CORPORATION
发明人： Cali, James J. , Daily, William , Hawkins, Erika , Klaubert, Dieter , Liu, Jianquan , Meisenheimer, Poncho , Scurria, Michael , Shultz, John W. , Unch, James , Wood, Keith V. , Zhou, Wenhui , Valley, Michael P.
IPC分类号： C12Q1/66 , C07D277/66
CPC分类号： C07D277/66 , C12Q1/66 , G01N2500/00

94. 发明公开

EP2670739A1 BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF 有权
标题翻译： AS抗癌剂一起使用BENZOTHIAZOLHYBRIDE及其制造方法
公开(公告)号：EP2670739A1
公开(公告)日：2013-12-11
申请号：EP12707390.6
申请日：2012-02-03
申请人： Council Of Scientific & Industrial Research
发明人： KAMAL, Ahmed , MALLAREDDY, Adla , SURESH, Paidakula , SHETTI, Rajesh Venkata Chenna Rama Narasimha Chennam , PAL, Harish Chandra , SAXENA, AJjit Kumar
IPC分类号： C07D277/66 , C07D417/12 , A61K31/428 , A61P35/00
CPC分类号： C07D277/66 , C07D417/12
摘要： Compounds of general formula A useful as potential anticancer agents against human cancer cell lines and a process for the preparation thereof.

95. 发明授权

EP2139907B1 ELECTROLUMINESCENT METAL COMPLEX 有权转让
标题翻译：电致发光金属中心COMPLEX
公开(公告)号：EP2139907B1
公开(公告)日：2013-08-14
申请号：EP08708612.0
申请日：2008-02-04
申请人： BASF SE
发明人： WOLLEB, Annemarie , WOLLEB, Heinz
IPC分类号： C09K11/06 , H05B33/14 , C07F15/00
CPC分类号： C07D233/64 , C07D233/90 , C07D235/12 , C07D235/30 , C07D263/48 , C07D263/56 , C07D263/57 , C07D263/58 , C07D277/46 , C07D277/66 , C07D277/82 , C07F15/0033 , C09K11/06 , C09K2211/1007 , C09K2211/1029 , C09K2211/1033 , C09K2211/1037 , C09K2211/1044 , C09K2211/1059 , C09K2211/1088 , C09K2211/1092 , C09K2211/185 , H01L51/0085 , H01L51/5016 , H05B33/14
摘要： Metal complexes of the formula I or I′ [LDH]nM[L]m (I) [LTH](M[L]p)2 (I1) wherein n is an integer 1 or 2, m and p each is an integer 1 or 2, the sum (n+m) being 2 or 3, M is a metal with an atomic weight of greater than 40 such as Iridium, L is a ligand as described in claim 1, and LDH is a bidentate ligand of the formula I1 and LTH is a dimer of LDH, binding to 2 metal atoms M, of the formula II′ wherein W is selected from O, S, NR4, CR5R6, X is N or CR7, Y is selected from O, S, NR8; and further residues are as defined in claim 1, show good light emitting efficiency in electroluminescent applications.

96. 发明公开

EP2562155A1 NOVEL HYDROXAMIC ACID DERIVATIVE 有权转让
标题翻译： NEW异羟肟酸
公开(公告)号：EP2562155A1
公开(公告)日：2013-02-27
申请号：EP11772045.8
申请日：2011-04-20
申请人： Taisho Pharmaceutical Co., Ltd. , Toyama Chemical Co., Ltd.
发明人： TAKASHIMA, Hajime , TSURUTA, Risa , YABUUCHI, Tetsuya , OKA, Yusuke , URABE, Hiroki , SUGA, Yoichiro , TAKAHASHI, Masato , UNEUCHI, Fumito , KOTSUBO, Hironori , SHOJI, Muneo , KAWAGUCHI, Yasuko
IPC分类号： C07C259/06 , A61K31/166 , A61K31/337 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/4015 , A61K31/402 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/407 , A61K31/415 , A61K31/416
CPC分类号： C07C233/83 , C07C235/84 , C07C237/36 , C07C259/06 , C07C271/22 , C07C271/28 , C07C309/30 , C07C311/08 , C07C317/28 , C07C317/44 , C07C323/41 , C07C323/62 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2601/18 , C07C2602/08 , C07D205/04 , C07D205/12 , C07D207/10 , C07D207/12 , C07D207/27 , C07D207/327 , C07D209/08 , C07D209/12 , C07D209/14 , C07D209/44 , C07D209/52 , C07D211/14 , C07D211/18 , C07D211/38 , C07D211/46 , C07D211/56 , C07D211/70 , C07D213/38 , C07D213/40 , C07D213/54 , C07D213/61 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/74 , C07D213/81 , C07D215/14 , C07D217/04 , C07D217/12 , C07D231/12 , C07D231/56 , C07D233/61 , C07D235/04 , C07D257/04 , C07D261/08 , C07D263/14 , C07D263/32 , C07D263/56 , C07D265/30 , C07D265/36 , C07D265/38 , C07D267/10 , C07D271/12 , C07D277/20 , C07D277/30 , C07D277/62 , C07D277/66 , C07D285/12 , C07D295/08 , C07D295/12 , C07D295/14 , C07D295/16 , C07D305/06 , C07D305/08 , C07D307/14 , C07D307/18 , C07D307/52 , C07D307/54 , C07D307/78 , C07D307/81 , C07D307/82 , C07D307/87 , C07D309/04 , C07D309/14 , C07D317/30 , C07D317/60 , C07D319/18 , C07D319/20 , C07D333/24 , C07D405/06 , C07D413/06 , C07D471/04 , C07D471/10 , C07D487/08 , C07D491/20 , C07D498/04 , C07D498/08 , C07F9/091
摘要： Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof:

97. 发明授权

EP2280706B1 LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES 有权
标题翻译：脂蛋白脂酶激活与苯衍生物的组合物
公开(公告)号：EP2280706B1
公开(公告)日：2013-01-02
申请号：EP08753022.6
申请日：2008-05-14
申请人： Otsuka Pharmaceutical Factory, Inc.
发明人： NEAGU, Irina , OHLMEYER, Michael , PARADKAR, Vidyadhar, M. , SAIONZ, Kurt, W. , IWATA, Koushi , OKAMURA, Takashi , SHIBUTANI, Tadao
IPC分类号： A61K31/4164 , A61K31/4184 , A61K31/4188 , A61K31/428 , A61K31/4745 , A61K31/519 , A61P3/04 , A61P3/06 , C07D233/58 , C07D235/18 , C07D277/66 , C07D471/04 , C07D487/04 , C07D513/04
CPC分类号： A61K31/519 , A61K31/4164 , A61K31/4184 , A61K31/4188 , A61K31/428 , A61K31/429 , A61K31/437 , A61K31/4745 , C07D233/56 , C07D233/58 , C07D235/18 , C07D277/66 , C07D471/04 , C07D487/04 , C07D513/04

98. 发明公开

EP2129654A4 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR 有权
标题翻译：使用ANAGONISTEN DES GLUCAGONREZEPTORS
公开(公告)号：EP2129654A4
公开(公告)日：2012-08-01
申请号：EP08729528
申请日：2008-02-11
申请人： METABASIS THERAPEUTICS INC
发明人： GOMEZ-GALENO JORGE E , REDDY RAJA K , VAN POELJE PAUL D , LEMUS ROBERT HUERTA , NGUYEN THANH HUU , GROTE MATTHEW P , DANG QUN , HECKER SCOTT J , MALI VENKAT REDDY , CHEN MINGWEI , SUN ZHILI , BOYER SERGE HENRI , LI HAIQING , CRAIGO WILLIAM
IPC分类号： C07C307/02 , A61K31/185 , A61P3/06 , A61P3/10 , C07C309/11 , C07C309/15 , C07C317/44 , C07C323/62
CPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
摘要： The present invention provides for novel compounds of Formula I and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as their use in methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistence and hyperglycemia.
摘要翻译：本发明提供具有胰高血糖素受体拮抗剂或反向激动剂活性的新颖的式I化合物及其药学上可接受的盐和共晶体。本发明进一步提供包含其的药物组合物以及它们在治疗，预防，延迟发病时间或降低发生或进展一种或多种胰高血糖素受体拮抗剂的疾病或病症的风险的方法中的用途被指出，包括I型和II型糖尿病，胰岛素抵抗和高血糖。

99. 发明授权

EP1421389B1 NEUROFIBRILLARY LABELS 有权
标题翻译：神经纤维MARKER
公开(公告)号：EP1421389B1
公开(公告)日：2012-05-02
申请号：EP02720102.9
申请日：2002-03-20
申请人： WisTa Laboratories Ltd.
发明人： WISCHIK, Claude, Michel , HARRINGTON, Charles, Robert , RICKARD, Janet, Elizabeth , HORSLEY, David
IPC分类号： G01N33/68 , C07D277/62 , G01N33/58 , C07D279/18
CPC分类号： C07D417/12 , C07D277/66 , C07D279/20 , G01N33/583 , G01N33/6896
摘要： Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of 'blocking ligands' to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.

100. 发明公开

EP2264018A3 Thioflavin derivatives for use in the diagnosis of Alzheimer's disease 有权
标题翻译： Thioflavinderivate用于诊断阿尔茨海默病
公开(公告)号：EP2264018A3
公开(公告)日：2012-04-25
申请号：EP10185669.8
申请日：2001-08-24
申请人： University of Pittsburgh of the Commonwealth System of Higher Education
发明人： Klunk, William, E. , Mathis, Chester, A., JR. , Wang, Yanming
IPC分类号： C07D277/66 , C07D277/64 , A61K49/00 , A61K31/428 , A61K51/04 , A61P25/28 , G01N33/534
CPC分类号： A61K31/5415 , A61K31/428 , A61K51/0497 , C07B2200/05 , C07D277/64 , C07D277/66
摘要： This invention relates to novel thioflavin derivatives of the structure useful in, for example, in vivo imaging of patients having neuritic plaques, as well as pharmaceutical compositions comprising the thioflavin derivatives and method for synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accum

ulation of neuritic plaques are prevalent. The Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式